Systemic sclerosis is an autoimmune connective tissue disease, which is characterised by
immune dysregulation and progressive fibrosis that typically affects the skin, with variable …

Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing
a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function …

The aim was to update the 2009 European League against Rheumatism (EULAR)
recommendations for the treatment of systemic sclerosis (SSc), with attention to new …

Objective Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized
controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in …

Abstract Background Systemic sclerosis (SSc) is a rare connective tissue disease with a
heterogeneous clinical course. Interstitial lung disease (ILD) is a common manifestation of …

The introduction of biologic DMARDs into rheumatology has resulted in a substantial
reduction of the burden of many rheumatic diseases. In the slipstream of the success …

Objectives Assess the efficacy and safety of tocilizumab in patients with systemic sclerosis
(SSc) in a phase II study. Methods Patients with SSc were treated for 48 weeks in an open …

It has been reported that corticosteroid therapy was effective in the management of severe
acute respiratory syndrome (SARS) and the Middle East Respiratory Syndrome (MERS) …

The lung is a common site of complications of systemic connective tissue disease (CTD),
and lung involvement can present in several ways. Interstitial lung disease (ILD) and …

Highlights•Solid organ transplantation (SOT) patients or patients with active ADs have been
largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …